Arcturus Therapeutics Holdings Inc. — Q1 2021 Form 10-Q
Business context and reporting period. This unaudited filing covers the three months ended March 31, 2021, with comparisons to Q1 2020. Arcturus is a clinical-stage mRNA medicines company developing vaccines and treatments for rare liver and respiratory diseases. It reported one operating segment and had no approved commercial products described in the filing.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Collaboration revenue | $2.1 million | $2.6 million; down 19.6% |
| Research and development expense, net | $50.1 million | $7.9 million |
| General and administrative expense | $9.7 million | $4.2 million |
| Total operating expenses | $59.8 million | $12.1 million |
| Net loss | $56.3 million | $9.8 million |
| Basic and diluted net loss per share | $2.15 | $0.67 |
| Net cash used in operating activities | $43.0 million | $11.9 million |
| Cash and cash equivalents at quarter-end | $466.8 million | $462.9 million at December 31, 2020 |
Liquidity and debt. Current assets were $470.0 million and current liabilities were $53.3 million at March 31, 2021. Long-term debt, net of current portion, was $58.1 million; the balance sheet also included $3.1 million of current debt within accrued liabilities. The company drew approximately $46.6 million under a Singapore Economic Development Board (EDB) loan in January. Management said working capital should fund operations for at least the next 12 months from issuance of the financial statements. The filing does not report a gross margin or provide a revenue/profit forecast.
Material changes and operating developments
- R&D expense rose sharply, driven principally by LUNAR-COV19 development and manufacturing, partnered discovery programs, and higher personnel and share-based compensation costs. LUNAR-COV19 R&D expense was $29.3 million, including $16.3 million of pre-launch inventory costs.
- Collaboration revenue declined mainly because of lower revenue from Takeda. Q1 revenue included $0.8 million from Janssen, $0.9 million from Ultragenyx, $0.2 million from CureVac, and $0.2 million from Takeda and other partners.
- Operating cash use increased alongside the larger net loss. Financing provided $47.0 million, primarily from the Singapore loan; investing cash use was $0.1 million. Cash, cash equivalents and restricted cash increased $3.9 million in the quarter.
- Arcturus issued shares valued at $5.0 million to Alexion for an exclusive license and expensed the amount as acquired in-process R&D because the asset had no alternative future use. It also recorded a $1.2 million equity-method investment gain related to Vallon and a $0.4 million foreign-currency gain on the Singapore loan.
Outlook, risks and contingencies
- Management expected continued losses and rising development costs. It anticipated the ARCT-021 Phase 3 trial could continue through 2021, with subject monitoring into 2022, and said the trial would be funded primarily or exclusively from cash reserves. If the vaccine received emergency use authorization, additional funding could be needed for commercialization.
- ARCT-021 Phase 2 enrollment was completed with 580 subjects dosed. Interim safety reviews supported continuation without amendment; interim immunogenicity data showed greater than 90% IgG seroconversion after a single 5 μg dose. Management cautioned that available data did not establish conclusive safety or efficacy.
- The company highlighted competition from COVID-19 vaccines already authorized and widely distributed, which could reduce demand for ARCT-021 or complicate trial enrollment. Trial timing, efficacy, regulatory approval, manufacturing, and access to future financing remain material uncertainties.
- The Singapore loan bears 4.5% interest and is generally repayable through a 10% royalty on LUNAR-COV19 net sales, subject to conditions that can trigger repayment of unpaid principal and interest. It is secured by specified assets and requires manufacturing deliveries, reporting, and audit milestones. The company reported compliance with loan covenants at quarter-end.
- Singapore EDB vaccine grants and the Cystic Fibrosis Foundation award carry delivery, audit, spending, or other conditions. Arcturus said it was negotiating amendments to the EDB grants. The filing also describes a $12.5 million non-refundable Israeli Ministry of Health payment recorded as deferred revenue, tied to a conditional vaccine supply arrangement.
- A former-employee lawsuit seeking $30.0 million was settled on May 5, 2021, after quarter-end; the company said insurance covered the settlement and it was not expected to create a material liability. The filing also noted the U.S. administration’s May 5 announcement supporting a COVID-19 vaccine patent waiver and the potential adverse effect on intellectual-property value.
Important facts for investors to verify
- Whether ARCT-021 advances to Phase 3, achieves persuasive efficacy and safety results, and remains commercially viable amid competitor vaccine availability.
- Actual cash burn and whether the stated runway remains adequate as vaccine, ARCT-810, LUNAR-CF, and other programs progress.
- Compliance with Singapore loan repayment, collateral, reporting, audit, and manufacturing-delivery terms, and the conditions governing any forgiveness.
- Progress toward the anticipated LUNAR-CF CTA submission and other stated development milestones, together with associated funding requirements.
- Whether collaboration revenue, grant funding, deferred revenue, and contingent milestone payments develop as expected; many potential milestones and royalties were excluded from recognized revenue because they remained uncertain.